Research programme: oral TNF-alpha inhibitors - Cosmo Pharmaceuticals
Alternative Names: CB-01-12; Oral anti-TNFα therapeutics - Cosmo PharmaceuticalsLatest Information Update: 16 Jul 2016
At a glance
- Originator Cosmo Pharmaceuticals
- Class
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Italy (PO, Tablet)